drugset / Trial / NCT01640054

A Long Term Study to Assess the Safety of Fostamatinib in Patients in Asia With Rheumatoid Arthritis

NCT01640054

Phase 2 Terminated 115 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long term safety and tolerability of fostamatinib in patients in Asia with rheumatoid arthritis (RA).

Timeline

Start
2012-07
Primary completion
2013-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Fostamatinib Small molecule 100 mg Oral

Indications